BioNTech SE - ADR vs Workday Inc — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Workday Inc trades at $141.24 (market cap $34.53B). The key difference: Workday Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| BNTX | WDAY | |
|---|---|---|
Market Cap | $22.86B | $34.53B |
Sector | Health | Technology |
52-Week High | $119.34 | $247.69 |
52-Week Low | $83.89 | $112.55 |
Enterprise Value | $6.53B | $33.98B |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Workday (WDAY) is trading at $144.87, up 4.26% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, 14.7% YoY subscription revenue growth, and expanding AI-driven contract values exceeding 200% year-over-year. Analyst consensus remains strongly positive with 55.55% buy ratings and a $157.30 price target, representing 8.6% upside potential from current levels.
WDAY presents a compelling growth opportunity with AI integration driving larger expansion deals and sustainable revenue growth. However, investors face risks including ongoing AI bias litigation, competitive pressures in enterprise software, and elevated valuation multiples. The stock's current technical overbought condition suggests potential near-term consolidation before further upside.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →